Jump to Navigation

Facebook Connect

User login


Dec, 2017

Nominations are now open for the National Lipid Association Board of Directors and Chapter officers and will be accepted until 5 p.m. EST on February 2, 2018.

To submit a nomination and for more information on the process, visit lipid.org/nominate.

No votes yet
Oct, 2017

The National Lipid Association announced on Wednesday its support of the Lipoprotein(a) Foundation’s efforts to promote a new ICD-10 Diagnostic-Code for high Lp(a).

The NLA believes the new code will be beneficial in identifying lethal risk factors in patients. To further support this initiative, NLA members are encouraged to email the ICD-10 Coordination and Maintenance Committee before November 13, 2017. 

No votes yet
Aug, 2017

The National Lipid Association (NLA) welcomes the results of the REVEAL trial which demonstrated that reductions in cholesterol levels with anacetrapib were associated with a reduction in cardiovascular events.  Specifically, cholesterol drug anacetrapib produced reductions in low density lipoprotein (LDL) cholesterol levels, non-high density lipoprotein (non-HDL) cholesterol levels, lipoprotein(a) levels and a profound increase in high density lipoprotein (HDL) cholesterol levels.  These favorable lipid changes were associated with a significant reduction in cardiovascular events

Average: 5 (1 vote)


by Dr. Radut.